Epigenetic landscape in IDH1 mutant glioma

نویسندگان

  • D. Wong
  • V. Leblanc
  • S. Chittaranjan
  • M. Marra
  • S. Yip
  • Ana Nikolic
  • John J. Kelly
  • Leslie E. Hamilton
  • Luolan Li
  • Sitanshu Gakkhar
  • Misha Bilenky
  • Annaick Carles
  • Alireza Heravi-Moussavi
  • Stephanie Cho
  • Baljit Kamoh
  • Angela Tam
  • Richard Moore
  • Andy Mungall
  • Steven Jones
  • Marco Marra
  • Stephen Yip
  • Martin Hirst
چکیده

A1 Investigations of the functional interactions between CIC and ATXN1L in Oligodendroglioma D. Wong, V. Leblanc, S. Chittaranjan, M. Marra, S. Yip BC Cancer Agency, UBC, Vancouver, BC, Canada doi:10.1017/cjn.2017.2 Oligodendroglioma (ODG) is a subtype of low grade glioma marked by unique clinical and genomic characteristics including slow predictable progression, IDH mutation, and 1p19qcodeletion. ODGs are more sensitive to treatment leading to a favorable prognosis. Recently, mutations in CIC, a gene found on chromosome 19q, have been found in up to 70% of IDH mutated, 1p19q-codeleted ODGs. The high frequency of CIC mutations in a hemizygous state indicates that loss or altered function of the CIC protein may be crucially associated with the unique biology of ODG. Previous studies of CIC have shown this protein to be a transcriptional repressor of ETS transcription factors and a negative regulator of the MAPK pathway. CIC and ataxin-1-like (ATXN1L) are also closely involved in the pathology of spinocerebellar ataxia (SCA). However, their relationship and role in brain tumour biology has yet to be elucidated. In this study, we explore the molecular, proteomic, and functional relationship between CIC and ATXN1L which may lead to unique insights on the clinical behavior of ODG as well as identify potential molecular therapeutic targets in this enigmatic brain tumour.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.

Mutations in the metabolic enzymes isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) are frequently found in glioma, acute myeloid leukemia (AML), melanoma, thyroid cancer, and chondrosarcoma patients. Mutant IDH produces 2-hydroxyglutarate (2HG), which induces histone- and DNA-hypermethylation through inhibition of epigenetic regulators. We investigated the role of mutant IDH1 using the mouse tra...

متن کامل

Isocitrate dehydrogenase 1 R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype.

The CpG Island Methylator Phenotype (CIMP) is fundamental to an important subset of colorectal cancer; however, its cause is unknown. CIMP is associated with microsatellite instability but is also found in BRAF mutant microsatellite stable cancers that are associated with poor prognosis. The isocitrate dehydrogenase 1 (IDH1) gene causes CIMP in glioma due to an activating mutation that produces...

متن کامل

Metabolic alterations due to IDH1 mutation in glioma: opening for therapeutic opportunities?

O II 13% 1% Recently heterozygous mutations in the active site of the enzyme isocitrate dehydrogenase 1 (IDH1) were discovered in glioblastomas [1]. In cohorts of glioma patients the IDH1 mutation appeared to be a strong predictor of clinical outcome, overruling histological malignancy grade [2]. IDH1 is an enzyme of the tricarboxylic acid (TCA) cycle and is located in the cytosol, where it pro...

متن کامل

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives

Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes that convert isocitrate to α-ketoglutarate. IDH1/2 mutations define distinct subsets of cancers, including low-grade gliomas and secondary glioblastomas, chondrosarcomas, intrahepatic cholangiocarcinomas, and hematologic malignancies. Somatic point mutations in IDH1/2 confer a gain-of-function in cancer cells, resulting ...

متن کامل

Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.

Mutations in isocitrate dehydrogenase 1 (IDH1) or 2 (IDH2) are found in a subset of gliomas. Among the many phenotypic differences between mutant and wild-type IDH1/2 gliomas, the most salient is that IDH1/2 mutant glioma patients demonstrate markedly improved survival compared with IDH1/2 wild-type glioma patients. To address the mechanism underlying the superior clinical outcome of IDH1/2 mut...

متن کامل

Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance.

Isocitrate dehydrogenase 1 (IDH1) mutations occur in most lower grade glioma and not only drive gliomagenesis but are also associated with longer patient survival and improved response to temozolomide. To investigate the possible causative relationship between these events, we introduced wild-type (WT) or mutant IDH1 into immortalized, untransformed human astrocytes, then monitored transformati...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2017